MedTrace Logo

Analysis of Renal Impairment Characteristics and High-Risk Factors in Chronic Hepatitis B Patients on Long-Term Oral Nucleos(t)Ide Analogues

NCT07730905 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 300

Last updated 2026-07-28

No results posted yet for this study

Summary

This is a single-center retrospective observational study. A total of 300 patients with non-alcoholic fatty liver disease treated in our hospital will be included. We collect clinical data, laboratory indicators and imaging results, and analyze the correlation between long-term nucleoside antiviral drugs and renal function changes in patients. The study does not use any new intervention measures, and only conducts statistical analysis on existing medical record data.

Conditions

  • Non-alcoholic Fatty Liver Disease, Renal Function Impairment

Interventions

DRUG

Long-term oral nucleos(t)ide analogs antiviral therapy

Oral nucleos(t)ide analog antiviral drugs, including tenofovir alafenamide, tenofovir disoproxil fumarate, entecavir, used for long-term treatment of chronic hepatitis B virus infection. This is a retrospective observational study analyzing renal safety after long-term antiviral treatment.

Sponsors & Collaborators

  • Foshan Hospital of Traditional Chinese Medicine

    lead OTHER

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-09-04
Primary Completion
2025-12-31
Completion
2025-12-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07730905 on ClinicalTrials.gov